NAS
EWTX icon

Nykredit A/S’s Edgewise Therapeutics EWTX Stock Holding History

Nykredit A/S’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Buy
+356
New +$12.3K ﹤0.01% 1813

Other funds holding EWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nykredit A/S's EWTX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 356 shares worth $14.5K. The stake represents ﹤0.01% of the portfolio and ranks #1813 among its holdings.

135 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Nykredit A/S held 356 shares of Edgewise Therapeutics worth $14.5K as of Q2 2026.
  • Edgewise Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1813 holding.
  • 135 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.